Results obtained by Gilead and Arcus could rekindle interest in the anti-TIGIT modality, which has seen many setbacks in the ...

MFN-driven drug price reductions in the US are unlikely to have a big impact pharma R&D spending, experts agree.

Cognivia Signal will try to predict which patients are at risk of dropping out to give sponsors the opportunity to intervene.

The vaccine was generally well tolerated among the paediatric population, with no unexpected safety signals reported. Credit: PeopleImages/Shutterstock.com. Bavarian ...

Johnson & Johnson’s pipeline IL-23 blocker, icotrokinra, has met its primary endpoint in a Phase IIb study in ulcerative colitis, meaning the drug’s efficacy and safety will now be explored in the ...